Northstrive Biosciences Northstrive Biosciences, a unit of PMGC Holdings, acquired two myostatin targeting drugs – EL-22 and EL-32 – from South Korean firm MOA Life Plus last year.

Northstrive Biosciences Northstrive Biosciences, a unit of PMGC Holdings, acquired two myostatin targeting drugs - EL-22 and EL-32 - from South Korean firm MOA Life Plus last year. The company ...

Elevai Biosciences Elevai Biosciences, a unit of PMGC Holdings, acquired two myostatin targeting drugs - EL-22 and EL-32 - ...

Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model. A multifaceted approach is needed to reduce financial barriers to obesity ...

Tirzepatide combined with lifestyle modification reduced the highest number of obesity cases (45,609 per 100,000 eligible individuals), diabetes cases (20,854 per 100,000 eligible individuals ...

The appeal is the latest move in the compounders’ battle to continue making copies of tirzepatide and other GLP-1s, including semaglutide. The FDA declared an end to the 2-year-old tirzepatide ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c ...

In one of the first real-world studies, Tirzepatide shows impressive weight loss results for people without diabetes—shedding nearly 13% of body weight in just six months. Study: Real-world use ...

Adults with type 1 diabetes had greater declines in HbA1c and body weight 1 year after being prescribed semaglutide or tirzepatide. Randomized controlled trials are needed to assess efficacy and ...

1 This denial keeps in place the FDA’s declaratory order determining that the shortage of diabetes and weight-loss tirzepatide products has been resolved and phases out compounded tirzepatide ...